Caitong International Asset Management’s Nuvectis Pharma NVCT Stock Holding History

Caitong International Asset Management’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$276	Buy	+15	New	+$168	﹤0.01%	1916

Other funds holding NVCT

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Caitong International Asset Management's NVCT Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Nuvectis Pharma (NVCT) in Q2 2026: 15 shares worth $276. The stake represents ﹤0.01% of the portfolio and ranks #1916 among its holdings.

83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

Caitong International Asset Management held 15 shares of Nuvectis Pharma worth $276 as of Q2 2026.
Nuvectis Pharma was a new Caitong International Asset Management position in Q2 2026.
Nuvectis Pharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1916 holding.
83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.